Jaguar Health, Inc. has announced a key development in its clinical trial for microvillus inclusion disease (MVID), a rare pediatric condition lacking approved therapies. The trial focuses on crofelemer, an oral solution aimed at reducing reliance on parenteral support (PS), crucial for MVID patients. The transition to the active treatment... Jaguar Health, Inc. has announced a key development in its clinical trial for microvillus inclusion disease (MVID), a rare pediatric condition lacking approved therapies. The trial focuses on crofelemer, an oral solution aimed at reducing reliance on parenteral support (PS), crucial for MVID patients. The transition to the active treatment-only phase underscores longer-term safety and efficacy as pivotal targets. First MVID patient enters active treatment extension phase with liquid crofelemer as adjunctive therapy. Jaguar Health focuses on rare pediatric disease treatment With orphan drug status already secured, Jaguar aligns its efforts toward pioneering treatments for these severe, life-long health concerns.R. P. Copyright © 2026 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets. Crofelemer Clinical Trial MVID Treatment Parenteral Support Pediatric Health

Original title: “Jaguar Health, Inc. (NASDAQ:JAGX) | Jaguar Health Advances Clinical Trial for MVID Treatment”